Cancer Letters
Volume 295, Issue 1 , Pages 44-53 , 1 September 2010

Lunasin promotes apoptosis in human colon cancer cells by mitochondrial pathway activation and induction of nuclear clusterin expression

  • Vermont P. Dia
    • ,
  • Elvira Gonzalez de Mejia

      Affiliations

    • Corresponding Author InformationCorresponding author. Address: Department of Food Science and Human Nutrition, 228 ERML, MC-051, 1201 West Gregory Drive, Urbana, IL 61801, USA. Tel.: +1 217 244 3196; fax: +1 217 265 0925.

Received 8 January 2010 ,Revised 10 February 2010 ,Accepted 11 February 2010.

References 

  1. Jemal A, Siegel R, Ward E, Hao YP, Xu JQ, Thun MJ. Cancer statistics. CA–A Cancer J. Clin. 2009;59:225–249
  2. Kim YS, Milner JA. Dietary modulation of colon cancer risk. J. Nutr. 2007;173:2576S–2579S
  3. Oba S, Nagata C, Shimizu N, Shimizu H, Kametami M, Takeyama N, et al. Soy product consumption and the risk of colon cancer: a prospective study in Tokoyama, Japan. Nutr. Cancer. 2007;57:151–157
  4. Spector D, Anthony M, Alexander D, Arab L. Soy consumption and colorectal cancer. Nutr. Cancer. 2003;47:1–12
  5. Akhter M, Iwasaki M, Yamaji T, Sasazuki S, Tsugane S. Dietary isoflavone and the risk of colorectal adenoma: a case-control study in Japan. Brit. J. Cancer. 2009;100:1812–1816
  6. Cotterchio M, Boucher BA, Manno M, Gallinger S, Okey A, Harper P. Dietary phytoestrogen intake is associated with reduced colorectal cancer risk. J. Nutr. 2006;136:3046–3053
  7. Ellington AA, Berhow M, Singletary KW. Induction of macroautophagy in human colon cancer cells by soybean B-group triterpenoid saponins. Carcinogenesis. 2005;26:159–167
  8. Kennedy AR, Billings PC, Wan XS, Newberne PM. Effects of Bowman-Birk inhibitor on rat colon carcinogenesis. Nutr. Cancer Int. J. 2002;43:74–186
  9. Galvez AF, Chen N, Macasieb J, de Lumen BO. Chemopreventive property of a soybean peptide (lunasin) that binds to deacetylated histones and inhibits acetylation. Cancer Res. 2001;61:7473–7478
  10. P Dia V, Wang W, Oh VL, de Lumen BO, Gonzalez de Mejia E. Isolation, purification and characterization of lunasin from defatted soybean flour and in vitro evaluation of its anti-inflammatory activity. Food Chem. 2009;114:108–115
  11. Gonzalez de Mejia E, Dia VP. Lunasin and lunasin-like peptides inhibit inflammation through suppression of NF-κB pathway in the macrophage. Peptides. 2009;30:2388–2398
  12. Gonzalez de Mejia E, Wang W, Dia VP. Lunasin, with an arginine–glycine-aspartic acid motif, causes apoptosis to L1210 leukemia cells by activation of caspase-3. Mol. Nutr. Food Res. 2010;54:1–9
  13. Hernandez-Ledesma B, Hsieh C, de Lumen BO. Lunasin, a novel seed peptide for cancer prevention. Peptides. 2009;30:426–430
  14. Lucie S, Elisabeth G, Stephanie F, Guy S, Amandine H, Corinne AR, et al. Clustering and internalization of integrin alpha(v)beta(3) with a tetrameric RGD-synthetic peptide. Mol. Ther. 2009;17:837–843
  15. Ruoslahti E. RGD and other recognition sequences for integrins. Ann. Rev. Cell Dev. Biol. 1996;12:697–715
  16. Moon C, Han JR, Park HJ, Hah JS, Kang JL. Synthetic RGDS peptide attenuates lipopolysaccharide-induced pulmonary inflammation by inhibiting integrin signaled MAP kinase pathways. Resp. Res. 2009;10:(Article 1)
  17. Anurahra CD, Kanno S, Hirano S. RGD peptide-induced apoptosis in human leukemia HL-60 cells required caspase-3 activation. Cell Biol. Toxicol. 2000;16:275–283
  18. Matsuki K, Sasho T, Nakagawa K, Tahara M, Sugioka K, Ochiai N, et al. RGD peptide-induced cell death of chondrocytes and synovial cells. J. Orthop. Sci. 2008;13:524–532
  19. Adams JM, Cory S. Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr. Opin. Immunol. 2007;19:488–496
  20. Hotchkiss RS, Strasser A, McDunn JE, Swanson PE. Mechanisms of disease: cell death. New Eng. J. Med. 2009;361:1570–1583
  21. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70
  22. Cohen GM. Caspases: the executioners of apoptosis. Biochem. J. 1997;326:1–16
  23. Salvensen GS, Dixit VM. Caspases: intracellular signaling by proteolysis. Cell. 1997;91:443–446
  24. Chen L, Zhuang G, Li W, Liu Y, Zhang J, Tian X. RGD-FasL induces apoptosis of pituitary adenoma cells. Cell Mol. Immunol. 2008;5:61–68
  25. Villard V, Kalvuzhniv O, Riccio O, Potekhin S, Melnik TN, Kajava AV, et al. Synthetic RGD-containing alpha-helical coiled coil peptides promote integrin-dependent cell adhesion. J. Pept. Sci. 2006;12:206–212
  26. Lu X, Lu D, Scully MF, Kakkar VV. Integrins in drug targeting-RGD templates in toxins. Curr. Pharm. Des. 2006;12:2749–2769
  27. Lam Y, Galvez A, de Lumen BO. LunasinTM suppresses E1A-mediated transformation of mammalian cells but does not inhibit growth of immortalized and established cancer cell lines. Nutr. Cancer. 2003;47:88–94
  28. Buckley CD, Pilling D, Henriquez NV, Parsonage G, Threlfall K, Scheel-Toellner D, et al. RGD peptides induce apoptosis by direct caspase-3 activation. Nature. 1999;397:534–539
  29. Stark GR, Taylor WR. Control of the G2/M transition. Mol. Biotechnol. 2006;32:227–248
  30. Chen X, Plasencia C, Hou Y, Neamiti N. Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J. Med. Chem. 2005;48:1098–1106
  31. Yang W, Meng L, Wang H, Chen R, Wang R, Ma X, et al. Inhibition of proliferative and invasive capacities of breast cancer cells by ariginine–glycine–aspartic acid peptide in vitro. Oncol. Rep. 2006;15:113–117
  32. Skladanowski A, Come M, Sabisz M, Escargueil AE, Larsen AK. Down-regulation of DNA topoisomerase II-α leads to prolonged cell cycle transit in G2 and early M phases and increased survival to microtubule-interacting agents. Mol. Pharmacol. 2005;68:625–634
  33. Niculescu AB, Chen X, Smeets M, Hengst L, Prives C, Reed SI. Effects of p21 (Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol. Cell Biol. 1998;18:629–643
  34. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G(2) arrest after DNA damage. Science. 1998;282:1497–1501
  35. Johnson IT. Anticarcinogenic effects of diet-related apoptosis in the colorectal mucosa. Food Chem. Toxicol. 2002;40:1171–1178
  36. Hector S, Prehn JHM. Apoptosis signaling proteins as prognostic biomarkers in colorectal cancer: a review. Biochim. Biophys. Acta. 2009;1795:117–129
  37. Violette S, Poulain L, Dussaulx E, Pepin D, Faussat AM, Chambaz J, et al. Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Intl. J. Cancer. 2002;98:498–504
  38. Yang X, Zheng F, Xing H, Gao Q, Wei W, Lu Y, et al. Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and overexpression of antiapoptotic proteins in ovarian cancer. J. Cancer Res. Clin. Oncol. 2004;130:423–428
  39. Sinicrope FA, Ruan SB, Cleary KR, Stephes LC, Lee JJ, Levin B. Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 1995;55:237–241
  40. Han HS, Park YM, Hwang TS. Differential expression of Bcl-2, Bcl-XL and p53 in colorectal cancer. J. Gastroenterol. Hepatol. 2006;21:1108–1114
  41. Gross A, Jockel J, Wei MC, Korsmeyer SJ. Enforced dimerization of Bax results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J. 1998;17:3878–3885
  42. Wei MC, Zong WX, Cheng EHY, Linsten T, Panoutsakopoulou V, Ross AJ, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science. 2001;292:727–730
  43. Nehls O, Okech T, Hsieh CJ, Enzinger T, Sarbia M, Borchard F, et al. Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX. Brit. J. Cancer. 2007;96:1409–1418
  44. Nehls O, Okech T, Hsieh CJ, Sarbia M, Borchard F, Gruenagel HH, et al. Low BAX protein expression correlates with disease recurrence in preoperatively irradiated rectal carcinoma. Intl. J. Radiat. Oncol. Biol. Phys. 2005;61:85–91
  45. Allen C, Sharman WM, La Madeliene C, van Lier JE, Weber JM. Attenuation of photodynamically induced apoptosis by an RGD containing peptide. Photochem. Photobiol. Sci. 2002;1:246–254
  46. Pucci S, Bonanno E, Pichiorri F, Angeloni C, Spagnoli LG. Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene. 2004;23:2298–2304
  47. B. Shannan, M. Seifert, K. Leskov, J. Willis, D. Boothman, W. Tilgen, J. Reichrath, Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer, Cell Death Diff. 3 (2006) 12–19.
  48. Leskov KS, Klokov DY, Li J, Kinsella TJ, Boothman DA. Synthesis and functional analyses of nuclear clusterin, a cell death protein. J. Biol. Chem. 2003;274:11590–11600
  49. Chen T, Turner J, McCarthy S, Scaltriti M, Bettuzzi S, Yeatman TJ. Clusterin-mediated apoptosis is regulated by adenomatous polyposis coli and is p21 dependent but p53 independent. Cancer Res. 2004;64:7412–7419
  50. Prueffer FG, Lizarraga F, Maldonado V, Melendez-Zajgla J. Participation of OmiHtra2 serine-protease activity in the apoptosis induced by cisplatin on SW480 colon cancer cells. J. Chemother. 2008;20:348–354
  51. Dia VP, Torres S, De Lumen BO, Erdman JW, Gonzalez de Mejia E. Presence of lunasin in plasma of men after soy protein consumption. J Agric. Food Chem. 2009;57:1260–1266

PII: S0304-3835(10)00098-4

doi: 10.1016/j.canlet.2010.02.010

Cancer Letters
Volume 295, Issue 1 , Pages 44-53 , 1 September 2010

Article Tools

* Image Usage & Resolution